The U.S. Court of Appeals for the Fifth Circuit recently ruled in NicQuid, L.L.C. v. FDA, No. 24-60272 (5th Cir. Aug. 19, 2026), that the U.S. Food and Drug Administration’s (FDA) “comparative efficacy standard” is a substantive rule that was adopted in violation of the Administrative Procedure Act’s (APA) notice-and-comment rulemaking requirements. The NicQuid decision notably creates a circuit split with the Ninth Circuit, which recently held in Drip More LLC v. FDA, No. 21-71380 (9th Cir. Aug.
Bryan Haynes
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Bryan
Contact Bryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack